- Accueil >
- Publications >
- Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
Auteurs
Loic Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Emmanuelle Bompas, Yves Toiron, Luc Camoin, Olivier Mir, Valerie Laurence, Stephanie Clisant, Emilie Decoupigny, Jean-Yves Blay, Anthony Goncalves, Nicolas Penel